Last reviewed · How we verify
hand mixed vancomycin
Hand mixed vancomycin, developed by Washington University School of Medicine, is a marketed antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and continued relevance in treating bacterial infections. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | hand mixed vancomycin |
|---|---|
| Also known as | Vancomycin |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hand mixed vancomycin CI brief — competitive landscape report
- hand mixed vancomycin updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI